| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Standard BioTools Inc.$0.83
+0.02 (+2.42%)
D 21Pipeline Score Diagnostics · Commercial
Market Cap
402.08 M
EPS
-0.25
P/E Ratio
-
Value Trade
4.16 M
SEC Financials
Q1 2026Dilution Risk
Revenue
21.15 M
R&D Expenses
2.12 M
Operating CF
-46.60 M
Total Assets
639.11 M
Total Liabilities
77.99 M
Equity
561.12 M
D/E Ratio
12,345
4.41 %
Week
9.24 %
1 Month
-10.43 %
3 Month
-20.16 %
6 Month
-82.3 %
5 Year
-92.37 %
All Time
Cash Data
Cash Position
455.18 M
Monthly Burn
15.53 M
Runway
27.9 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
3.29 M
52 Week Range
0.87 - 1.72
% held by Insiders
3.86 %
% held by Institutions
76.11 %
Enterprise Value
-23.61 M
Total Shares
390.09 M
Short %
5.89 %
Float Shares
222.74 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D21
Pipeline Score $30M
Pipeline ValueValuation Signal
1
Drugs Scored0.1x
rNPV / MCap Top 19%
Micro Cap (rank 734 of 905)
Percentile RankStandard BioTools Inc. faces pipeline headwinds (21/100), with $76M risk-adjusted pipeline value, led by Spanish Black Radish product in Healthy (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spanish Black Radish product Unknown | Healthy | Phase 1 | NCT02137590 | 8% | $76M | COMPLETED | 20 | - | - | Nov 1, 2011 | - | May 14, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LAB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
LAB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LAB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LAB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LAB Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
LAB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LABStandard BioTools Reports First Quarter 2026 Financial Results
Standard BioTools Inc. reported its financial results for Q1 2026, showcasing a revenue of $21.1 million, reflecting a 5% increase from the previous year. The company achieved a 54% reduction in operating loss and a 78% improvement in adjusted EBITDA, indicating progress towards profitability. Despite challenges in instruments revenue, the overall financial health appears strong with substantial cash reserves to support future growth.
Read more →LABStandard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
Standard BioTools Inc. has announced the release date for its first quarter 2026 financial results, which will be published on May 5, 2026, after the U.S. market closes. The company specializes in next-generation technologies that aid biomedical research, particularly in oncology and immunology. This announcement reflects the company's ongoing commitment to transparency and investor engagement.
Read more →LABStandard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results
Standard BioTools Inc. reported strong financial results for Q4 and full year 2025, highlighting better-than-expected performance and operational efficiencies. The company anticipates revenue between $80 million and $85 million for fiscal year 2026. The strategic sale of SomaLogic to Illumina is expected to provide flexibility for future growth, although risks remain regarding integration and market conditions.
Read more →LABStandard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Standard BioTools Inc. has announced that it will release its fourth quarter and full year 2025 financial results on February 24, 2026, after the U.S. market closes. The company is known for its advanced technologies that assist biomedical researchers in developing better medicines. Their focus includes oncology, immunology, and immunotherapy, serving various research institutions globally.
Read more →LABStandard BioTools Completes Sale of SomaLogic to Illumina
Standard BioTools has completed the sale of SomaLogic to Illumina for $350 million upfront, with potential total proceeds of up to $425 million. The transaction is expected to enhance Standard BioTools' financial position, allowing for future growth and acquisitions. However, the company faces risks related to stockholder litigation and the realization of expected benefits.
Read more →LABStandard BioTools Reports Third Quarter 2025 Financial Results
Standard BioTools Inc. reported its third quarter financial results for 2025, highlighting a strong performance and a focus on operational efficiency. The company is implementing a restructuring plan aimed at achieving over $40 million in annual cost savings by 2026. Despite workforce reductions, the outlook remains positive with expected revenue between $165 million and $175 million for the fiscal year.
Read more →LABStandard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study
Standard BioTools has partnered with Precision Health Research, Singapore, to utilize its SomaScan 11K Assay for the PRECISE-SG100K study, which will analyze 100,000 plasma samples. This collaboration aims to enhance precision medicine and healthcare outcomes in Singapore by leveraging extensive participant data. The initiative is expected to set a new standard for population-scale proteomics.
Read more →LABStandard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025
Standard BioTools Inc. will announce its second quarter 2025 financial results on August 11, 2025. A conference call will be held at 4:30 p.m. ET to discuss these results and the company's operational progress. The call will be accessible via phone and online webcast, with an archive available afterward.
Read more →LABStandard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina
Standard BioTools has announced the strategic sale of SomaLogic to Illumina for up to $425 million, including $350 million upfront. This move aims to simplify the company's operations and achieve adjusted EBITDA break-even. The deal retains certain commercialization rights for Standard BioTools, positioning it for future growth. The transaction is expected to close in the first half of 2026, pending regulatory approvals.
Read more →LABStandard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series
Standard BioTools Inc. has announced the launch of its inaugural Proteomics Roundtable Series, aimed at fostering discussions on advancements in proteomics. The first session will feature insights from researchers involved in a significant cancer study. Future sessions will cover various topics related to proteomic technologies and their applications in healthcare.
Read more →LABStandard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025
Standard BioTools Inc. has announced new product innovations in proteomics at the AACR Annual Meeting 2025. The launch includes the SomaScan Select 3.7K Assay and the CyTOF XT PRO system, aimed at enhancing translational and clinical research. The company emphasizes its commitment to advancing cancer research through innovative solutions and extensive participation in the conference.
Read more →Competitive Position
How LAB ranks across every disease it competes inCompetitive Position is a premium feature
See how LAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial